Interesting talk. This has actually been known for a long time - doxorubicin treatment is one of the ways people interested in studying senescence induce it in an animal or cell. Doxorubicin doesn't just induce senescence in the heart, but in tissues all over the body and it is one of the reasons we think bisantrene might help protect from doxorubicin in more than just the heart.
I should add that the reason doctors often don't see the damage to the heart until years later is they are using the wrong measure. When you focus on the entire cardiovascular system using VO2peak you can see the damage 1 month after treatment - it is the measures like LVEF that takes years to appear.
We should probably send Laura some bisantrene
RAC Price at posting:
$1.06 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)